Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2024
Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
According to MRAResearch’s new survey, global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market research.
Key companies engaged in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics industry include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Segment by Type
Stimulants
Non-stimulants
Pediatric and Adolescents
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
According to MRAResearch’s new survey, global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market research.
Key companies engaged in the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics industry include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Segment by Type
Stimulants
Non-stimulants
Segment by Application
Pediatric and Adolescents
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices